US2010210542A1PendingUtilityA1
Methods of Treating Disorders with Group I mGluR Antagonists
Individually held — no corporate assignee on recordPriority: Apr 2, 2001Filed: Jan 15, 2010Published: Aug 19, 2010
Est. expiryApr 2, 2021(expired)· nominal 20-yr term from priority
A61K 31/195A61K 31/00A61K 31/472A61P 25/00A61P 25/18A61K 31/44A61K 31/4725A61K 31/198
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.
Claims
exact text as granted — not AI-modified1 . A method of treating a human having a learning deficit, comprising the step of administering to the human a composition that includes a Group I mGlur antagonist.
Join the waitlist — get patent alerts
Track US2010210542A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.